A New Era in Swine Health: The Cirbloc® M Hyo Vaccine
2025 marks a pivotal year for the swine industry in Spain with the introduction of the groundbreaking Cirbloc® M Hyo vaccine. Authorized by the European Commission, this innovative dual-action vaccine targets two of the most prevalent threats to pig respiratory health: porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (Mhyo).
What sets Cirbloc® M Hyo apart is its cutting-edge formulation. The Mhyo component leverages the same strain used in Hyogen’s M.hyo vaccine, while the PCV2 fraction is derived from the PCV2d genotype, the most dominant strain currently found in pig farms worldwide. This strategic combination ensures the vaccine is both relevant and effective.
The vaccine’s standout features include its rapid immune response and sustained protection. Immunity against Mhyo kicks in just three weeks post-vaccination, while protection against PCV2 begins in as little as two weeks. Both defenses remain robust for up to 23 weeks, offering long-term safeguarding against these debilitating diseases.
PCV2 and Mhyo are notorious for their global prevalence and devastating impact on pig respiratory systems. Vaccination has emerged as a cornerstone in combating these pathogens. Clinical trials for Cirbloc® M hyo have demonstrated a notable reduction in viremia and viral loads in PCV2-affected tissues, such as lymphoid organs and lungs. Additionally, the vaccine has been shown to mitigate the severity of lung lesions caused by Mhyo infections.
Beyond the vaccine itself, Ceva Salud Animal has expanded its support through the Ceva Lung Program (CLP).This comprehensive system focuses on the detection and management of lung injuries linked to Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae. In 2024, CLP achieved a remarkable milestone by evaluating over one million pig lungs in Spanish slaughterhouses, underscoring its critical role in the industry.
Ceva Salud Animal, a global leader in animal health and a key player in the European swine sector, continues to solidify its reputation as a pioneer in respiratory health solutions. With Cirbloc® M Hyo and the CLP program, the company is empowering the pork industry to tackle health challenges head-on, ensuring healthier livestock and more lasting farming practices.
